These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32316335)

  • 21. Animal models of multiple system atrophy.
    Fernagut PO; Tison F
    Neuroscience; 2012 Jun; 211():77-82. PubMed ID: 21963351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards translational therapies for multiple system atrophy.
    Kuzdas-Wood D; Stefanova N; Jellinger KA; Seppi K; Schlossmacher MG; Poewe W; Wenning GK
    Prog Neurobiol; 2014 Jul; 118():19-35. PubMed ID: 24598411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple system atrophy of the cerebellar type: clinical state of the art.
    Lin DJ; Hermann KL; Schmahmann JD
    Mov Disord; 2014 Mar; 29(3):294-304. PubMed ID: 24615754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple system atrophy.
    Fanciulli A; Stankovic I; Krismer F; Seppi K; Levin J; Wenning GK
    Int Rev Neurobiol; 2019; 149():137-192. PubMed ID: 31779811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy.
    Ettle B; Kerman BE; Valera E; Gillmann C; Schlachetzki JC; Reiprich S; Büttner C; Ekici AB; Reis A; Wegner M; Bäuerle T; Riemenschneider MJ; Masliah E; Gage FH; Winkler J
    Acta Neuropathol; 2016 Jul; 132(1):59-75. PubMed ID: 27059609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.
    Valera E; Monzio Compagnoni G; Masliah E
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):95-106. PubMed ID: 26924723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MOBP and HIP1 in multiple system atrophy: New α-synuclein partners in glial cytoplasmic inclusions implicated in the disease pathogenesis.
    Bettencourt C; Miki Y; Piras IS; de Silva R; Foti SC; Talboom JS; Revesz T; Lashley T; Balazs R; Viré E; Warner TT; Huentelman MJ; Holton JL
    Neuropathol Appl Neurobiol; 2021 Aug; 47(5):640-652. PubMed ID: 33368549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy.
    Herrera-Vaquero M; Bouquio D; Kallab M; Biggs K; Nair G; Ochoa J; Heras-Garvin A; Heid C; Hadrovic I; Poewe W; Wenning GK; Klärner FG; Schrader T; Bitan G; Stefanova N
    Biochim Biophys Acta Mol Basis Dis; 2019 Nov; 1865(11):165513. PubMed ID: 31319154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy.
    Fernagut PO; Meissner WG; Biran M; Fantin M; Bassil F; Franconi JM; Tison F
    Synapse; 2014 Mar; 68(3):98-106. PubMed ID: 24243499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies.
    Fernagut PO; Dehay B; Maillard A; Bezard E; Perez P; Pavy-Le Traon A; Rascol O; Foubert-Samier A; Tison F; Meissner WG
    Neurobiol Dis; 2014 Jul; 67():133-9. PubMed ID: 24727096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on multiple system atrophy.
    Stankovic I; Kuijpers M; Kaufmann H
    Curr Opin Neurol; 2024 Aug; 37(4):400-408. PubMed ID: 38828714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A historical review of multiple system atrophy with a critical appraisal of cellular and animal models.
    Marmion DJ; Peelaerts W; Kordower JH
    J Neural Transm (Vienna); 2021 Oct; 128(10):1507-1527. PubMed ID: 34613484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review: Multiple system atrophy: emerging targets for interventional therapies.
    Stefanova N; Wenning GK
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):20-32. PubMed ID: 26785838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Region-Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy.
    Bassil F; Monvoisin A; Canron MH; Vital A; Meissner WG; Tison F; Fernagut PO
    Mov Disord; 2015 Nov; 30(13):1802-12. PubMed ID: 26260627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The neuropathology, pathophysiology and genetics of multiple system atrophy.
    Ahmed Z; Asi YT; Sailer A; Lees AJ; Houlden H; Revesz T; Holton JL
    Neuropathol Appl Neurobiol; 2012 Feb; 38(1):4-24. PubMed ID: 22074330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple system atrophy.
    Wenning GK; Geser F
    Rev Neurol (Paris); 2003 May; 159(5 Pt 2):3S31-8. PubMed ID: 12773886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropathology of multiple system atrophy: new thoughts about pathogenesis.
    Jellinger KA
    Mov Disord; 2014 Dec; 29(14):1720-41. PubMed ID: 25297524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A mouse model of adult-onset multiple system atrophy.
    Tanji K; Miki Y; Mori F; Nikaido Y; Narita H; Kakita A; Takahashi H; Wakabayashi K
    Neurobiol Dis; 2019 Jul; 127():339-349. PubMed ID: 30910745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy.
    Valera E; Spencer B; Fields JA; Trinh I; Adame A; Mante M; Rockenstein E; Desplats P; Masliah E
    Acta Neuropathol Commun; 2017 Jan; 5(1):2. PubMed ID: 28057080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sobetirome rescues α-synuclein-mediated demyelination in an in vitro model of multiple system atrophy.
    Mészáros L; Himmler M; Schneider Y; Arnold P; Dörje F; Schubert DW; Winkler J
    Eur J Neurosci; 2024 Jan; 59(2):308-315. PubMed ID: 38086536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.